ライフサイエンスコーパス: monoclonal

1 rgen immune complexes were formed with human monoclonal allergen-specific IgE and Bet v 1.

2 We apply these methods to both a monoclonal and an antibody mixture.

3 nd sensitivities of the R5, G12 and Skerritt monoclonal and two polyclonal antibodies to well-defined

4 Binding of specific monoclonal anti-DARC antibodies and recombinant DBP to C

5 Pharmacologic activation of FGFR1 with a monoclonal anti-FGFR1 antibody (R1MAb1) normalized BP an

6 The monoclonal anti-immunoglobulin E (IgE) antibody, omalizu

7 ecting mice from A. baumannii infection, but monoclonal anti-OMP antibodies have not been developed,

8 Avelumab, a human monoclonal anti-PD-L1 antibody, has shown promising anti

9 Both PCA and PN were stained with monoclonal anti-PSMA antibody (clone 3E6, 1:100, M3620).

10 Importantly, a monoclonal anti-TIM-4 Ab promoted allograft tolerance, a

11 osuppression with alemtuzumab (aIRR = 3.12), monoclonal antibodies (aIRR = 1.83), or polyclonal antib

12 demic, and induction of broadly neutralizing monoclonal antibodies (bNAbs) against HCV is a major goa

13 EMENT Calcitonin gene-related peptide (CGRP) monoclonal antibodies (CGRP-mAbs) are capable of prevent

14 NT Recently, we reported that humanized CGRP monoclonal antibodies (CGRP-mAbs) prevent activation and

15 h to migraine treatment, humanized anti-CGRP monoclonal antibodies (CGRP-mAbs) were developed to redu

16 new class of such drugs, humanized anti-CGRP monoclonal antibodies (CGRP-mAbs), were found to be effe

17 dditional infectious pathogens.DNA-delivered monoclonal antibodies (DMAbs) can be produced by muscle

18 Monoclonal antibodies (mAb) of anti-human IL-1b and anti

19 Agonistic monoclonal antibodies (mAb) targeting the T-cell recepto

20 er are promising epitopes for targeting with monoclonal antibodies (mAb).

21 In recent years, monoclonal antibodies (mAbs) able to reinvigorate antitu

22 The classical view of therapeutic monoclonal antibodies (mAbs) against tumor-associated an

23 r interaction with a group of alpha-JUNV GPC monoclonal antibodies (MAbs) and mouse antisera against

24 he ability to bind RBD-specific neutralizing monoclonal antibodies (MAbs) and the DPP4 receptor, and

25 l Hodgkin lymphoma (cHL) patients, anti-PD-1 monoclonal antibodies (mAbs) are increasingly being used

26 Monoclonal antibodies (mAbs) are large heterogeneous mol

27 Monoclonal antibodies (mAbs) are widely used and powerfu

28 Monoclonal antibodies (mAbs) can destroy tumors by recru

29 The Fc domain of IgG monoclonal antibodies (mAbs) contains two methionine res

30 In the course of screening monoclonal antibodies (MAbs) for their ability to delive

31 Intraperitoneally administered radiolabeled monoclonal antibodies (mAbs) have been tested in several

32 Epitope mapping of the neutralizing monoclonal antibodies (mAbs) indicated major contacts wi

33 Recombinant monoclonal antibodies (mAbs) manufactured from immortali

34 undreds of labeled hybridoma cells producing monoclonal antibodies (mAbs) specific for a hapten were

35 Monoclonal antibodies (mAbs) targeting Notch protein act

36 is to evaluate the antibacterial activity of monoclonal antibodies (MAbs) targeting outer membrane pr

37 For Pseudomonas aeruginosa, human monoclonal antibodies (mAbs) targeting the Psl biofilm e

38 Two human monoclonal antibodies (MAbs) that neutralized DENV4 were

39 Using a panel of monoclonal antibodies (MAbs) that recognize known major

40 Here, we generated a panel of eight murine monoclonal antibodies (MAbs) utilizing a prime-boost vac

41 obtain large quantities of antigen-specific monoclonal antibodies (mAbs) were first established in t

42 and tumor delivery of a panel of anti-EphA2 monoclonal antibodies (mAbs) with and without drug conju

43 We report 3 LukAB-specific human monoclonal antibodies (mAbs) with distinct mechanisms of

44 mically conjugated to two different anti-HIV monoclonal antibodies (MAbs), anti-gp120 MAb 924 or anti

45 tibodies (PAbs) or RSV glycoprotein-specific monoclonal antibodies (MAbs), as determined by indirect

46 the design of antiviral therapies, including monoclonal antibodies (mAbs), have naturally relied exte

47 reened for antigenicity using four different monoclonal antibodies (MAbs), including PGT151.

48 nization through administration of exogenous monoclonal antibodies (mAbs).

49 rains, so induction of multiple neutralizing monoclonal antibodies (NAbs) targeting distinct epitopes

50 passive immunization with human neutralizing monoclonal antibodies (nmAbs) has made exciting gains: (

51 rolled protein-expressing cell lines using 6 monoclonal antibodies (SP142, E1L3N, 9A11, SP263, 22c3,

52 d by immunohistochemistry, using 2 different monoclonal antibodies against a major antigen of varicel

53 Neutralizing human monoclonal antibodies against alpha-toxin (AT) and clump

54 Notably, monoclonal antibodies against PfCelTOS strongly inhibite

55 tive enzyme-linked immunosorbent assays with monoclonal antibodies against PfLDH or PfIDEh showed det

56 old chip containing an antifouling layer and monoclonal antibodies against the toxin and, after washi

57 The Fc-region of monoclonal antibodies against TNF has immunosuppressive

58 ion of aGVHD-associated lymphangiogenesis by monoclonal antibodies against vascular endothelial growt

59 Monoclonal antibodies already in use or under investigat

60 proaches are emerging including antagonistic monoclonal antibodies and agonistic fusion proteins to i

61 asured by antigenic analysis with a panel of monoclonal antibodies and by detecting changes in oligom

62 nted in combination therapies with anti-CD20 monoclonal antibodies and open up novel avenues for the

63 ght into chemical degradation in full-length monoclonal antibodies and the high-resolution hydrogen-e

64 Monoclonal antibodies and vaccines targeting humoral res

65 roprotein convertase subtilisin/kexin type 9 monoclonal antibodies can reduce low-density lipoprotein

66 Here, we optimize DNA-delivered monoclonal antibodies consisting of two potent human IgG

67 The DNA-delivered monoclonal antibodies decrease bacterial colonization of

68 These studies support DNA-delivered monoclonal antibodies delivery as a potential strategy t

69 The DNA-delivered monoclonal antibodies exhibit indistinguishable potency

70 ransducer functionalized with antidengue NS1 monoclonal antibodies for rapid detection of the dengue

71 Lymphoblasts were isolated using monoclonal antibodies for the Human Transferring Recepto

72 DC-targeting vaccines, humanized recombinant monoclonal antibodies fused to Env gp140, were administe

73 Therapy of cancer with radiolabeled monoclonal antibodies has produced impressive results in

74 he PD-1/PD-L1 immune checkpoint pathway with monoclonal antibodies has provided significant advances

75 tinguished by amyloid conformation-dependent monoclonal antibodies have similarly distinct roles in p

76 Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anapl

77 nderstanding the potential benefits of PCSK9 monoclonal antibodies incremental to statins in on-going

78 o enable the detailed epitope mapping of two monoclonal antibodies known to recognize AGPs: JIM16 and

79 Therapeutic and diagnostic applications of monoclonal antibodies often require careful selection of

80 The mechanism of action of PCSK9 monoclonal antibodies on lipoprotein metabolism remains

81 c blockade of FcRn-albumin interactions with monoclonal antibodies or peptide mimetics, which cause h

82 nancies or solid tumors by administration of monoclonal antibodies or T cells engineered to express c

83 Monoclonal antibodies provide an attractive alternative

84 tment with anti-TNF-alpha or anti-IL-4Ralpha monoclonal antibodies restored the TH1- and TH2-induced

85 e a novel approach to produce conformational monoclonal antibodies selected to specifically react wit

86 and -B35 expression on platelets using human monoclonal antibodies specific for these antigens.

87 Agonistic monoclonal antibodies targeting 4-1BB have been develope

88 Although monoclonal antibodies targeting such ligands can block t

89 the envelope glycoprotein 1 (GP1) with JUNV monoclonal antibodies targeting the receptor binding sit

90 alf-life (eg, FVIII-Fc and PEGylated FVIII), monoclonal antibodies targeting tissue factor pathway in

91 for cancer are typically small molecules or monoclonal antibodies that act by inhibiting the activit

92 n immense interest in developing therapeutic monoclonal antibodies that act on GPCRs.

93 Using epitope mapping, we discovered mouse monoclonal antibodies that can discriminate between huma

94 make possible the rapid development of human monoclonal antibodies that could become a potent immedia

95 Here, we obtained two anti-A(H1N1)pdm09 HA monoclonal antibodies that failed to neutralize viruses

96 Monoclonal antibodies that neutralize TcdB function have

97 Monoclonal antibodies that neutralize toxin activity pro

98 Here we present three separate monoclonal antibodies that specifically recognize Abetap

99 ted nearly identical binding profiles to HCV monoclonal antibodies that target conserved neutralizing

100 he complementary binding region on all three monoclonal antibodies to be the CDR H3 loop of the Fab r

101 The recent successful use of monoclonal antibodies to block immune regulatory pathway

102 , we evaluated the capacity of anti-receptor monoclonal antibodies to deliver vaccine components to s

103 ither of these IVIG fragments, nor agonistic monoclonal antibodies to human Fas or Siglec-9 affected

104 We identify human monoclonal antibodies to O-antigens that are highly prot

105 the most widely used scaffold for developing monoclonal antibodies to treat human diseases.

106 haracterize the epitope specificities of two monoclonal antibodies used in an ELISA for the quantific

107 tested the binding breadth of the resulting monoclonal antibodies using a set of recombinant surface

108 In this study, a collection of high-affinity monoclonal antibodies was generated to boscalid.

109 All patients receiving anti-PD-1 monoclonal antibodies were identified using the Mayo Can

110 ultifunctional HNPs conjugated with anti-MG1 monoclonal antibodies were synthesized, and the coupling

111 e inhibitory RGMa, clinically relevant human monoclonal antibodies were systemically administered aft

112 Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic dr

113 anti-epidermal growth factor receptor (EGFR) monoclonal antibodies with radiotherapy (RT) to standard

114 or classes of effective agents in WM include monoclonal antibodies, alkylating agents, purine analogs

115 p53 is inaccessible to classical therapeutic monoclonal antibodies, an increasingly successful class

116 ic approaches using biologics like vaccines, monoclonal antibodies, and enzymes.

117 cluding small molecules, proteins, vaccines, monoclonal antibodies, and nucleic acids.

118 hnique to express antigen-specific felinized monoclonal antibodies, and the initial characterization

119 Compared to conventional monoclonal antibodies, knob-into-hole bispecific antibod

120 t given in combination with tumor-opsonizing monoclonal antibodies, KWAR23 greatly augments myeloid c

121 ave the potential to outperform conventional monoclonal antibodies, many bispecific antibodies have i

122 on SAB were determined using W6/32 and HC-10 monoclonal antibodies, respectively.

123 breadth of cross-reactive neutralization by monoclonal antibodies, whether engineered or isolated fr

124 ccine or treatment with one or a cocktail of monoclonal antibodies.

125 lbumin with nanomolar affinity for all three monoclonal antibodies.

126 cine development and the prophylactic use of monoclonal antibodies.

127 ations for biotherapies such as vaccines and monoclonal antibodies.

128 cloning and characterizing large numbers of monoclonal antibodies.

129 some inhibitors, immunomodulatory drugs, and monoclonal antibodies.

130 by a panel of amyloid conformation-specific monoclonal antibodies.

131 raxane) nanoparticles coated with commercial monoclonal antibodies.

132 ome inhibitors, immunomodulatory agents, and monoclonal antibodies.

133 ity in extracellular recognition of GPCRs by monoclonal antibodies.

134 ethodology to characterize residual HCPs in (monoclonal) antibodies by combining a novel sample prepa

135 d through radiolabeling of the anti-human TF monoclonal antibody (ALT-836) with (89)Zr.

136 and then perfused with a humanized anti-CD47 monoclonal antibody (CD47mAb) in the treatment group or

137 culatory cessation, then flushed with a CD47 monoclonal antibody (CD47mAb) in the treatment group, or

138 We previously described a monoclonal antibody (DX-2507) that binds to FcRn with hi

139 rinciple of this method is based on the BChE monoclonal antibody (MAb) capable of acting as both capt

140 ng low side effect cancer therapy based on a monoclonal antibody (mAb) conjugated with a near-infrare

141 Eculizumab, a humanized anti-complement C5 monoclonal antibody (mAb) for treatment of paroxysmal no

142 Anti-DC-SIGN monoclonal antibody (MAb) inhibited HHV-8 infection of i

143 Competitive binding of the human monoclonal antibody (mAb) LE2E9 revealed overlapping epi

144 An IgG1 monoclonal antibody (mAb) purified by Protein A column e

145 inked, via lysine or cysteine residues, to a monoclonal antibody (mAb) scaffold.

146 th the F(ab')2 form of the anti-RSV G 131-2G monoclonal antibody (MAb) show that mutating the CX3C mo

147 en-printed electrode (AuSPE), and afterwards monoclonal antibody (mAb) specific to l-kynurenine was c

148 Experimental monoclonal antibody (mAb) therapies have shown promise f

149 CD73 on the activity of the anti-HER2/ErbB2 monoclonal antibody (mAb) trastuzumab.

150 of DC-STAMP in periodontitis, anti-DC-STAMP-monoclonal antibody (mAb) was tested in a mouse model of

151 Administration approved the first biosimilar monoclonal antibody (mAb), Inflectra/Remsima (Celltrion)

152 We isolated a human monoclonal antibody (mAb), ZKA190, that potently cross-n

153 -molecular weight (HMW) fractions of an IgG1 monoclonal antibody (mAb).

154 Monoclonal antibody 10-1074 targets the V3 glycan supers

155 local administration at the inflamed site of monoclonal antibody 3-E7, which recognizes the pan-opioi

156 A. marginale infection of host cells, but a monoclonal antibody against 6-sulfo-sLe(x) fails to inhi

157 Fetal hepatocytes were isolated using a monoclonal antibody against a hepatic surface protein, l

158 l characterization of a functional felinized monoclonal antibody against feline panleukopenia virus.

159 A previous study suggested that the 18B7 monoclonal antibody against glucuronoxylomannan (GXM), t

160 ate the efficacy and safety of simtuzumab, a monoclonal antibody against LOXL2, in patients with IPF.

161 A monoclonal antibody against Nogo-A showed a positive eff

162 Evolocumab is a fully human, monoclonal antibody against PCSK9 that reduces low-densi

163 during long-term therapy with evolocumab, a monoclonal antibody against proprotein convertase subtil

164 Bevacizumab (Avastin(R)), a monoclonal antibody against vascular endothelial growth

165 Bevacizumab, a monoclonal antibody against VEGF, improves the proportio

166 the workflow to three-part assemblies for a monoclonal antibody and its single-chain antibody fragme

167 Different formats of an antibody (monoclonal antibody and the antigen binding fragments F(

168 ts who received daratumumab, a CD38-directed monoclonal antibody approved for the treatment of multip

169 that antisera from immunized mice inhibited monoclonal antibody binding to neutralizing epitopes.

170 been made in the development of vaccines and monoclonal antibody cocktails that target the Ebola coat

171 Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive

172 We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit o

173 Bevacizumab, a monoclonal antibody directed against VEGF, improves outc

174 Treatment with the monoclonal antibody E06 or with apolipoprotein A-I mimet

175 Idarucizumab, a monoclonal antibody fragment, was developed to reverse t

176 izing the Ncad extracellular domain with the monoclonal antibody GC-4 suppresses lateral dispersal an

177 ine (His-His) cross-links were discovered in monoclonal antibody HMW species.

178 ncement toward broader practical delivery of monoclonal antibody immunotherapeutics for additional in

179 efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patients wit

180 S-5745, a potent, highly selective humanized monoclonal antibody inhibitor of MMP9, has shown promise

181 The hydrophobicity of a monoclonal antibody is an important biophysical property

182 efficacy, and pharmacokinetics of anti-CD38 monoclonal antibody isatuximab given in 2 schedules (3,

183 A monoclonal antibody isolated from this cow harboured an

184 IIA (FcgammaRIIA), infusion of the HIT-like monoclonal antibody KKO increased fibrin and platelet de

185 An anti-LigB monoclonal antibody library exhibits cell binding and ba

186 manized anti-folate receptor alpha (FRalpha) monoclonal antibody linked to the tubulin-disrupting may

187 Our group generated the monoclonal antibody mAb-A4 against human embryonic stem

188 t glucagon receptor (GCGR) inhibition with a monoclonal antibody normalized blood glucose and beta-hy

189 The human monoclonal antibody opicinumab (BIIB033, anti-LINGO-1) h

190 Blockade, by either monoclonal antibody or tumor necrosis factor receptor ge

191 resistant to the potent HAstV-2-neutralizing monoclonal antibody PL-2 (MAb PL-2).

192 e interaction between GDF15 and GFRAL with a monoclonal antibody prevented the metabolic effects of G

193 therapy prompted a trial with the anti-CD20 monoclonal antibody rituximab.

194 ing aggregate types and content in different monoclonal antibody samples.

195 y of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell-der

196 was also shown to bind D25, a highly potent monoclonal antibody specific for the pre-F conformation.

197 of our method to analyze a high-purity NIST monoclonal antibody standard RM 8670 derived from a muri

198 of pyrrolobenzodiazepine dimers linked to a monoclonal antibody targeting CD33, which is expressed i

199 Avelumab, a human Ig-G1 monoclonal antibody targeting PD-L1 and approved in the

200 Pembrolizumab is a humanized monoclonal antibody targeting programmed cell death prot

201 hibit tumor growth in vitro and in vivo by a monoclonal antibody targeting the AGR2 self-dimerization

202 lular Hsp90alpha-Delta protein function by a monoclonal antibody targeting the fragment-5 region disr

203 -expressing xenografts, using the bispecific monoclonal antibody TF2 (anti-CEA x anti-histamine-succi

204 Girentuximab is a chimeric monoclonal antibody that binds carbonic anhydrase IX, a

205 PF-00547659 is a fully human monoclonal antibody that binds to human mucosal addressi

206 Avelumab (MSB0010718C) is a human IgG1 monoclonal antibody that binds to PD-L1, inhibiting its

207 nd by the Fab fragment of mAb35, a reference monoclonal antibody that causes experimental MG and comp

208 humanised, anti-interleukin 5 receptor alpha monoclonal antibody that directly and rapidly depletes e

209 inophilic, anti-interleukin-5 receptor alpha monoclonal antibody that has been shown to significantly

210 d risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by spec

211 anised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed d

212 Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B ce

213 We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expre

214 BACKGROUND & AIMS: MEDI2070 is a human monoclonal antibody that selectively inhibits interleuki

215 negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CR

216 Although the advent of monoclonal antibody therapy has had a positive effect in

217 Here we report studies using a monoclonal antibody to block IFN-alpha/beta receptor (IF

218 Inolimomab, a monoclonal antibody to CD25, has shown encouraging resul

219 An invasion inhibitory monoclonal antibody to CyRPA blocks binding of CyRPA to

220 erved even when the mice were treated with a monoclonal antibody to eliminate residual granulocyte ac

221 C) takes advantage of the selectivity of the monoclonal antibody to increase the efficacy of the chem

222 Evolocumab, a fully human monoclonal antibody to PCSK9 (proprotein convertase subt

223 Using a monoclonal antibody to plant cell wall xyloglucan, we sh

224 safety in the FOURIER trial of evolocumab, a monoclonal antibody to proprotein convertase subtilisin-

225 Infusion of a T-cell-depleting anti-CD8beta monoclonal antibody to the controller animals led to a s

226 Treatment of C57BL/6 or NOD mice with a monoclonal antibody to the CSF-1 receptor resulted in de

227 Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy signifi

228 effect of targeting this receptor using the monoclonal antibody TRC105, and find that in AML, TRC105

229 A control monoclonal antibody used for 70 analyses over 450 days d

230 the structure of the epitope recognized by a monoclonal antibody with opsonophagocytic activity and r

231 nts (eg, a MEK inhibitor and/or an anti-CD20 monoclonal antibody).

232 Newly constructed monoclonal antibody, 1G6-D7, against the dual lysine reg

233 last enrichment technique to isolate a human monoclonal antibody, 46B8 that neutralizes all IBVs test

234 1B/D agonist sumatriptan and a CGRP-blocking monoclonal antibody, attenuated the peripheral CGRP-indu

235 Bezlotoxumab, a human monoclonal antibody, binds to C. difficile toxin B (TcdB

236 A monoclonal antibody, designated LM26, binds to the cell

237 Alemtuzumab, a CD52-depleting monoclonal antibody, effectively inhibits relapsing mult

238 Omalizumab, an anti-immunoglobulin E monoclonal antibody, has transformed the management of m

239 ized anticarcinoembryonic antigen (anti-CEA) monoclonal antibody, labetuzumab, can be used as a tumor

240 hat addition of an integrin beta1-activating monoclonal antibody, P4G11, to invasive colorectal cance

241 FG-3019, an anti-CTGF monoclonal antibody, was used to inhibit CTGF.

242 sm of C. difficile toxin neutralization by a monoclonal antibody, which involves targeting a process

243 selective for the heavy and light chain of a monoclonal antibody, which when used consecutively, ensu

244 ment of improved therapeutic approaches, and monoclonal antibody-based drugs are potentially a powerf

245 t degree of specificity, particularly with a monoclonal antibody-based immunoassay.

246 lopment and technical validation of a rabbit monoclonal antibody-based sandwich immunoassay for human

247 re the modified beads (mouse anti-flavivirus monoclonal antibody-coated beads) in the microfluidic ch

248 Conclusion Targeted monoclonal antibody-conjugated HNPs can serve as a catal

249 ika virus with a highly specific immobilized monoclonal antibody.

250 HAstV are resistant to a virus-neutralizing monoclonal antibody.

251 tform was modified with anti-E. coli O157:H7 monoclonal antibody.

252 y, but no correlation with the anti-carp PAV monoclonal antibody.

253 ynthesised as peptides for the production of monoclonal antibody.

254 d nanoparticles conjugated with an anti-CD38 monoclonal antibody.

255 ceptor-null mice that were administered GcgR monoclonal antibody.

256 highlight the importance of CDCC and CDCP in monoclonal-antibody function and provide an experimental

257 py, we imaged secondary antibody labeling of monoclonal AQP4-IgGs with differing epitope specificity

258 The resulting conformational monoclonals are able to detect pathological oligomeric f

259 oup had a significantly higher prevalence of monoclonal B cell lymphocytosis, premalignant condition

260 all three Ugandan participants had absolute monoclonal B-cell count below one cell per muL, whereas

261 tive MBL, as well as differences in absolute monoclonal B-cell count between the two cohorts.

262 Passive transfer of monoclonal bNAb proteins can confer protection in animal

263 In monoclonal cases, the dominant clone varied between 11%

264 infection and demonstrates that an effective monoclonal CD4 T cell response may successfully guide su

265 protection provided by spherical growth of a monoclonal colony during exposure to phages that prolife

266 ently develop mixed cryoglobulinemia (MC), a monoclonal expansion of immunoglobulin M (IgM)(+) autore

267 progenitors and sensitized the cells with a monoclonal Fel d 1-specific IgE.

268 The high frequency of monoclonal gammopathy in adult patients with C3 glomerul

269 Hematological diagnosis was monoclonal gammopathy of renal significance in 30 (60%),

270 Monoclonal gammopathy of undetermined significance (MGUS

271 onsecutive patients with multiple myeloma or monoclonal gammopathy of unknown significance sequential

272 Monoclonal gammopathy was of IgG type in 47 (94%) patien

273 me is characterized by an urticarial rash, a monoclonal gammopathy, and clinical, histological, and b

274 tivated pDCs produce IFN as well as how both monoclonal HIV-specific Abs and Abs produced in natural

275 A widely used commercial monoclonal IgE antibody, SPE-7 IgE from Sigma, was found

276 Addition of monoclonal IgE to cultured PBMCs significantly (P = .04)

277 g autoimmune peripheral neuropathy caused by monoclonal IgM autoantibodies that recognize the carbohy

278 glomerulopathy (C3G) emphasizes the role of monoclonal immunoglobulin (MIg) in the occurrence of ren

279 and adapted interface for the attachment of monoclonal immunoglobulin G (IgGNS1) and to favor specif

280 Among 34 patients (91.9%) with monoclonal immunoglobulin G gammopathy, 20 (58.8%) had k

281 ted that both colorectal adenoma and CRC are monoclonal in origin, and the CRCs further diversified i

282 d cytokine profiles and found that, although monoclonal iNKT cells differentiated into all functional

283 multiple culture time point samples from six monoclonal isolates, and single nucleotide polymorphism

284 ave an underlying clonal mast cell disorder (monoclonal mast cell activation syndrome or systemic mas

285 ify those with systemic mastocytosis but not monoclonal mast cell activation syndrome.

286 oduction of an orthogonal alkyne handle into monoclonal or polyclonal antibodies from different speci

287 ic mutations show that the metastases have a monoclonal origin and descend from a common 'metastatic

288 und that both the adenoma and cancer were of monoclonal origin, and both shared partial mutations in

289 rect immunofluorescence assays that combined monoclonal (outer surface protein A) and polyclonal anti

290 , and sequence analysis of randomly selected monoclonal phages revealed two conserved peptide sequenc

291 In-depth characterization of one of these monoclonal, polyreactive natural antibodies, the IgM clo

292 lude that only one antibody, the rarely used monoclonal PPZ0506, specifically targets ERbeta in immun

293 Monoclonal T. gondii-specific CD8 T cells adoptively tra

294 Expression of this near-monoclonal TCR in a Jurkat cell-transfection system vali

295 Although each individual monoclonal TCR showed an inherent subset distribution pr

296 alpha-Gal is part of the IgE-reactive monoclonal therapeutic antibody cetuximab (CTX) and is a

297 gG subclasses are monitored with Fc-specific monoclonal whole IgG (FcMonoIgG).

298 st study to identify cross neutralizing scFv monoclonals with CD4bs and N332 glycan specificities fro

299 enables generation of a large repertoire of monoclonals with diverse specificities.

300 hage display or derived from human/humanized monoclonals, with constant regions.